Myriad Genetics Stock Net Asset
| MYGN Stock | USD 23.26 0.10 0.43% |
Myriad Genetics fundamentals help investors to digest information that contributes to Myriad Genetics' financial success or failures. It also enables traders to predict the movement of Myriad Stock. The fundamental analysis module provides a way to measure Myriad Genetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Myriad Genetics stock.
Myriad | Net Asset |
Myriad Genetics Company Net Asset Analysis
Myriad Genetics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Myriad Genetics Net Asset | 1.2 B |
Most of Myriad Genetics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Myriad Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Myriad Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Myriad Genetics is extremely important. It helps to project a fair market value of Myriad Stock properly, considering its historical fundamentals such as Net Asset. Since Myriad Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Myriad Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Myriad Genetics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Myriad Total Assets
Total Assets |
|
Based on the recorded statements, Myriad Genetics has a Net Asset of 1.2 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Myriad Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Myriad Genetics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Myriad Genetics could also be used in its relative valuation, which is a method of valuing Myriad Genetics by comparing valuation metrics of similar companies.Myriad Genetics is currently under evaluation in net asset category among related companies.
Myriad Genetics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Myriad Genetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Myriad Genetics' managers, analysts, and investors.Environmental | Governance | Social |
Myriad Genetics Institutional Holders
Institutional Holdings refers to the ownership stake in Myriad Genetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Myriad Genetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Myriad Genetics' value.| Shares | Goldman Sachs Group Inc | 2023-12-31 | 2.2 M | Sei Investments Co | 2023-12-31 | 2.2 M | Disciplined Growth Investors Inc | 2024-03-31 | 2.1 M | Geode Capital Management, Llc | 2023-12-31 | 1.9 M | D. E. Shaw & Co Lp | 2024-03-31 | 1.3 M | Pictet Asset Manangement Sa | 2024-03-31 | 1.2 M | Nuveen Asset Management, Llc | 2023-12-31 | 1 M | Charles Schwab Investment Management Inc | 2024-03-31 | 986.5 K | Northern Trust Corp | 2023-12-31 | 942.1 K | Blackrock Inc | 2023-12-31 | 14.7 M | Vanguard Group Inc | 2024-03-31 | 10 M |
Myriad Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.066 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 2.14 B | ||||
| Shares Outstanding | 90.51 M | ||||
| Shares Owned By Insiders | 2.09 % | ||||
| Shares Owned By Institutions | 97.91 % | ||||
| Number Of Shares Shorted | 5.1 M | ||||
| Price To Earning | 31.95 X | ||||
| Price To Book | 2.24 X | ||||
| Price To Sales | 2.33 X | ||||
| Revenue | 678.4 M | ||||
| Gross Profit | 476.4 M | ||||
| EBITDA | (67.8 M) | ||||
| Net Income | (112 M) | ||||
| Cash And Equivalents | 205.1 M | ||||
| Cash Per Share | 2.54 X | ||||
| Total Debt | 145 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | 8.40 X | ||||
| Cash Flow From Operations | (106.3 M) | ||||
| Short Ratio | 10.08 X | ||||
| Earnings Per Share | (2.80) X | ||||
| Price To Earnings To Growth | 1.40 X | ||||
| Target Price | 25.27 | ||||
| Number Of Employees | 2.7 K | ||||
| Beta | 1.97 | ||||
| Market Capitalization | 2.1 B | ||||
| Total Asset | 1.2 B | ||||
| Retained Earnings | (366.2 M) | ||||
| Working Capital | 137.4 M | ||||
| Current Asset | 314.5 M | ||||
| Current Liabilities | 72.3 M | ||||
| Net Asset | 1.2 B |
About Myriad Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Myriad Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Myriad Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Myriad Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Myriad Genetics Piotroski F Score and Myriad Genetics Altman Z Score analysis. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.Note that the Myriad Genetics information on this page should be used as a complementary analysis to other Myriad Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Myriad Stock analysis
When running Myriad Genetics' price analysis, check to measure Myriad Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myriad Genetics is operating at the current time. Most of Myriad Genetics' value examination focuses on studying past and present price action to predict the probability of Myriad Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Myriad Genetics' price. Additionally, you may evaluate how the addition of Myriad Genetics to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Myriad Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.80) | Revenue Per Share 9.114 | Quarterly Revenue Growth 0.116 | Return On Assets (0.07) | Return On Equity (0.29) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.